Clinical Trial Detail

NCT ID NCT02532192
Title A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

Burkitt lymphoma

diffuse large B-cell lymphoma

follicular lymphoma

Therapies

Rituximab

Cisplatin

Dexamethasone

Cytarabine

Fluconazole

Belinostat

Age Groups:

No variant requirements are available.